NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies.
about
A novel CXCL10-based GPI-anchored fusion protein as adjuvant in NK-based tumor therapyPhenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6.NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy.Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.Bitter Melon Enhances Natural Killer-Mediated Toxicity against Head and Neck Cancer Cells.Autologous immune enhancement therapy in Philadelphia chromosome positive acute lymphoblastic leukemia.KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma.When unity makes strength: Combinatorial NK cell-based immunotherapies against melanomaSurvivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells.Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension.Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.Multicellular assembly and light-regulation of cell-cell communication by conjugated polymer materials.NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention.
P2860
Q27308798-0C4278FD-0781-46E7-B035-AFCA658B1991Q35034899-2F7E8FCD-60A1-4123-8A1A-F9853AA2D2AEQ35719855-03F8E509-9FA3-40F2-8B93-9092D274510BQ36799788-5012E513-5315-4D46-830A-E4790ECF066AQ37098286-2A175833-FD6A-46A3-9EF5-E88433AA0989Q37558627-12AA9384-03E4-40F3-8607-EF5AEF6C47BFQ38039112-69208B74-9C42-4E7E-AED0-A4F765185BDAQ38394496-9A3E82A1-82A9-47A9-92D2-313CBBB2E5A3Q38705138-B109D186-6E20-4BC0-B42A-8315214F5BD7Q41869977-16C671A7-E772-47F7-9A11-A8EAD8F164BBQ41913332-6976F019-5179-4F06-89CE-BD057C94B1F0Q42726223-7115526E-A2F1-454A-AEBA-FA68EDCBB3A8Q42796228-40ABA1CE-022E-4E6C-8753-E9CCB6AEA4A8Q44027694-B262E70E-D7E2-4E8F-B5D0-D18294106C18Q44389468-06426875-F43D-420B-BD5C-7A960DC9C34CQ46052565-9EF65C06-ED55-49D3-A5D6-D96CED6E32B2Q54369697-483C98E2-29DF-441D-9D62-F1DE1779CA03
P2860
NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
NK cells sense tumors, course ...... uences for NK-based therapies.
@en
type
label
NK cells sense tumors, course ...... uences for NK-based therapies.
@en
prefLabel
NK cells sense tumors, course ...... uences for NK-based therapies.
@en
P2093
P2860
P356
P1433
P1476
NK cells sense tumors, course ...... uences for NK-based therapies.
@en
P2093
Anne Caignard
Aurélie Perier
Giulia Fregni
Marie-Françoise Avril
P2860
P356
10.4161/ONCI.1.1.18312
P577
2012-01-01T00:00:00Z